Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study.

被引：0
|
作者：
Mustacchi, Giorgio
Cazzaniga, Marina Elena
Giordano, Monica
Garrone, Ornella
Beano, Alessandra
Del Mastro, Lucia
Livi, Lorenzo
Iezzi, Laura
Michelotti, Andrea
Turletti, Anna
Riccardi, Ferdinando
De laurentiis, Michele
Marchetti, Paolo
Biganzoli, Laura
Montemurro, Filippo
Romagnoli, Emanuela
De Placido, Sabino
Pronzato, Paolo
机构：
[1] Univ Trieste, Trieste, Italy
[2] Hosp San Gerardo, Oncol Unit, Monza, MB, Italy
[3] Santa Anna Hosp, Como, Italy
[4] S Croce & Carle Teaching Hosp, Med Oncol, Cuneo, Italy
[5] AOU Citta Salute & Sci, Oncol Dept, Turin, Italy
[6] IRCCS AOU San Martino IST, Med Oncol, Genoa, Italy
[7] Univ Florence, Florence, Italy
[8] Dept Expt & Clin Sci, Chieti, Italy
[9] Univ Pisana, Azienda Osped, Oncol Unit 1, Pisa, Italy
[10] ASLTO1 Osped Martini, Med Oncol, Turin, Italy
[11] AORN A Cardarelli Hosp, Naples, Italy
[12] Natl Canc Inst Fdn Pascale, Naples, Italy
[13] Sapienza Univ, St Andrea Hosp, Dept Clin & Mol Med, Rome, Italy
[14] Hosp Prato, Sandro Pitigliani Med Oncol Dept, Ist Toscano Tumori, Prato, Italy
[15] FPO IRCC, Candiolo Canc Inst, Invest Clin Oncol, Candiolo, Italy
[16] Osped Macerata, UOC Oncol, Macerata, Italy
[17] Univ Naples Federico II, Naples, Italy
[18] San Martino IST Ist Naz Ric Cancro, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1049
引用
收藏
页数：6
相关论文
共 5 条
  • [1] First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study.
    Pronzato, Paolo
    Mustacchi, Giorgio
    Giordano, Monica
    Garrone, Ornella
    Del Mastro, Lucia
    Natoli, Clara
    Turletti, Anna
    Romagnoli, Emanuela
    Bologna, Alessandra
    Mocerino, Carmela
    Alu, Massimiliano
    De Angelis, Claudia
    Aversa, Caterina
    Arpino, Grazia
    Taverniti, Cristiana
    Biganzoli, Laura
    Meattini, Icro
    Piezzo, Michela
    Cazzaniga, Marina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.
    Mustacchi, Giorgio
    Cazzaniga, Marina Elena
    Romagnoli, Emanuela
    Montemurro, Filippo
    De laurentiis, Michele
    Riccardi, Ferdinando
    Turletti, Anna
    Beano, Alessandra
    De Angelis, Claudia
    Graziano, Vincenzo
    Livi, Lorenzo
    Del Mastro, Lucia
    Biganzoli, Laura
    Garrone, Ornella
    De Placido, Sabina
    Marchetti, Paolo
    Pronzato, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Choices of first-line therapy in her2-ve advanced breast cancer (abc) patients (pts). prelimary results of the gim-13-ambra study
    Cazzaniga, M. E.
    Mustacchi, G.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    Del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Riccardi, F.
    Paolo, P.
    De Placido, S.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13-AMBRA Study
    Cazzaniga, M.
    Mustacchi, G.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Ferdinando, R.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, M.
    Romagnoli, E.
    De Placido, S.
    Pronzato, P.
    Biganzoli, L.
    Bisagni, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Fulvestrant (FUL) as first-line therapy in HR1ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
    Pronzato, P.
    Mustacchi, G.
    Riccardi, F.
    Turletti, A.
    Michelotti, A.
    Natoli, C.
    Livi, L.
    Del Mastro, L.
    Donadio, M.
    Garrone, O.
    Giordano, M.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, F.
    Romagnoli, E.
    De Placido, S.
    Biganzoli, L.
    Cazzaniga, M.
    ANNALS OF ONCOLOGY, 2017, 28
1